The influence of citrate concentration on the quality of plasma obtained by automated plasmapheresis: A prospective study

Transfusion

Volumn 39, Issue 11-12, 1999, Pages 1266-1270

  Beeck, H ^b   Becker, T ^b   Kiessig, S T ^b   Kaeser, R ^b   Wolter, K ^b   Hellstern, P ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; HEMOSTASIS; HUMAN; NORMAL HUMAN; PLASMAPHERESIS; QUALITY CONTROL;

ADULT; ANTICOAGULANTS; ANTITHROMBINS; BETA-THROMBOGLOBULIN; CITRATES; EVALUATION STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA; PLASMAPHERESIS; PROSPECTIVE STUDIES;

EID: 0032715616     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1999.39111266.x     Document Type: Article

References (19)

1. Wallace EL, Surgenor DM, Hao HS, et al. Collection and transfusion of blood components in the United States, 1989. Transfusion 1993;33:139-44.
2. Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-47.
3. VanAken WG. The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products. Transfus Med Rev 1997;11:6-14.
4. Weiss HJ. A study of the cation and pH dependent stability of factor VIII in plasma. Thromb Diath Haemorrh 1965;14:32-51.
5. Rock GA, Cruickshank WH, Tackaberry ES, et al. Stability of factor VIII:C in plasma: the dependence on protease activity and calcium. Thromb Res 1983;29:521-35.
6. Mikaelsson ME, Forsman N, Oswaldsson UM. Human factor VIII: a calcium-linked protein complex. Blood 1983;62:1006-15.
7. Prowse C, Waterston YG, Dawes J, Farrugia A. Studies on the procurement of blood coagulation factor VIII. In vitro studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang 1987;52:257-64.
8. Suontaka AM, Akerblom O, Blomback M, et al. Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant. Vox Sang 1996;71:97-102.
9. Solheim BG, Bergerud UE, Kjeldsen-Kragh J, et al. Improved blood preservation with 0.5CPD erythro-sol. Coagulation factor VIII activity and erythrocyte quality after delayed separation of blood. Vox Sang 1998;74:168-75.
10. Farrugia A, Douglas S, James J, et al. Use of plasma with high levels of ionised calcium in the production of model scale coagulation factor concentrates. Thromb Haemost 1990;64:374-8.
11. McIntosh RV, Foster PR. The effect of solution formulation on the stability and surface interactions of factor VIII during plasma fractionation. Transfus Sci 1990;11:55-66.
12. Rock G, Tittley P, Fuller V. Effect of citrate anticoagulants on factor VIII levels in plasma. Transfusion 1988;28:248-52.
13. Rock G, McCombie N, Fuller V, Tittley P. Comparison of manual and machine plasmapheresis techniques. Plasma Ther Transfus Technol 1988;9:337-42.
14. Rosen S, Andersson M, Blomback M, et al. Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost 1985;54:818-23.
15. Aronson DL, Chang P. Activated factor VIII in therapeutic preparations: analysis by ultracentrifugation. Vox Sang 1996;71:142-9.
16. Carlebjörk G, Blombäck M, Pihlstedt P. Freezing of plasma and recovery of factor VIII. Transfusion 1986;26:159-62.
17. Blomback B, Blomback M. Purification and stabilization of factor V. Nature 1963;198:886-7.
18. Duguid J, Winkelman L, Feldman P, Brady A. The effect of citrate anticoagulants on apheresed plasma. Transfus Sci 1989;10:287-93.
19. Evans D, Walker T, Evans H. Pilot scale (300 kg) fractionation of plasma for factor VIII and factor IX. Transfus Sci 1989;10:313-9.